profit from every $100 of sales.
$0$100
Amarin
$11.74+1.12% today
-25.3% in 1 year
1-year low $11.321-year high $16.98
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Amarin sold, what it kept, and what it did with the cash.
Sales went from $369 million in 2022 to $214 million in 2025, with -$38.8 million of profit last year.
SalesProfit
Amarin vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Amarin | No profit yet | ||
 Vertex Pharmaceuticals | 35.3× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 21.1× · Fair price | ||
 CSL | 22.2× · Fair price |
AI analysis
An AI analyst reads Amarin's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 369 | 307 | 229 | 214 | |
| 242 | 166 | 81 | 121 | |
| -92 | -57 | -92 | -14 | |
| -101 | -51 | -74 | -33 | |
| -106 | -59 | -82 | -39 | |
| -5.20 | -3.00 | -4.00 | -1.80 | |
| 65.7% | 53.9% | 35.6% | 56.6% | |
| -25.0% | -18.4% | -40.2% | -6.5% | |
| -28.7% | -19.3% | -35.9% | -18.2% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 886 | 832 | 685 | 671 |
| Cash | 218 | 199 | 121 | 135 |
| Total debt | 10 | 9 | 8 | 6 |
| Total liabilities | 291 | 280 | 199 | 211 |
| 595 | 552 | 486 | 459 | |
| 20 | 20 | 21 | 21 | |
| -13.5% | -7.6% | -12.3% | -6.1% | |
| -17.8% | -10.7% | -16.9% | -8.4% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -180 | 7 | -31 | 7 | |
| 1 | 1 | – | – | |
| -181 | 6 | -31 | 7 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 26 | 16 | 18 | 14 |
Valuation
- –
- –
- –
- 0.7×
- 2.3×
- 73.4×
- –
- 1.4%
- -7.9%
- 0.0%
Profitability
- 56.6%
- -6.5%
- -18.2%
- -1.1%
- -7.8%
- -10.3%
- -7.3%
- -5.2%
- -8.0%
- 8.6%
Growth
- −16.7%
- –
- +121.7%
- –
- +1.2%
Financial health
- -3.9×
- 0.01
- 0.9%
- –
- 3.48
- 2.46
- 0.33
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 29%of 948
Bottom 17%of 871
Bottom 6%of 868
Top 49%of 985
What analysts expect
- Average price target
- $2.17
- Range
- $1.50 – $3.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 29, 2026 | -0.09 | 0.01 | −1,000.0% |
| Feb 25, 2026 | 0.01 | 0.07 | −85.7% |
| Oct 29, 2025 | 0.01 | 0.08 | −87.5% |
| Jul 30, 2025 | -0.03 | -0.66 | +95.5% |
| May 7, 2025 | -0.04 | -1.12 | +96.4% |
| Mar 12, 2025 | -2.40 | -1.20 | −100.0% |
| Oct 30, 2024 | -1.00 | -1.00 | +0.0% |
| Jul 31, 2024 | 0.20 | 0.10 | +100.0% |
News
Amarin analysis links Vascepa adherence to greater, longer-lasting heart benefitsSeeking Alpha · Aug 30, 2026The newest story we have is from Aug 30, 2026.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
28No pass
Benjamin Graham
71Pass
Philip Fisher
38No pass
Peter Lynch
28No pass
Joel Greenblatt
0No pass
Charlie Munger
33No pass
Terry Smith
24No pass
Questions about Amarin
Is Amarin a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Amarin AI analysis
What does Amarin do?
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. It is in Biotechnology.
Does Amarin pay a dividend?
No. Amarin does not pay a dividend at the moment.
Is Amarin stock halal?
No. Amarin does not pass our halal screen: its cash and receivables are 53% of its market value, at or above the 49% limit. How we check
How has Amarin stock done over the past year?
Down 25.3% over the past twelve months, to $11.74. It traded between $11.32 and $16.98 and is 30.9% below its high.
Who are Amarin's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Amarin's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.